[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients]

Strahlenther Onkol. 2020 Mar;196(3):286-288. doi: 10.1007/s00066-019-01574-y.
[Article in German]
No abstract available

Publication types

  • Comment

MeSH terms

  • Aminopyridines
  • Breast Neoplasms*
  • Humans
  • Perimenopause
  • Purines

Substances

  • Aminopyridines
  • Purines
  • ribociclib